Search General Info
Search Education
Search Partnering Companies
![BIF](/sites/default/files/2023-05/230112-bio-bif-logo-color-horiz.jpg)
OYE has repurposed and reformulated a injectable drug product that accelerates emergence from anesthesia roughly 50% faster than the current standard of care. The downstream impact of the intervention is a 30-50% reduction in the length of stay in recovery of 30-90 minutes, reduction in uncompensated care, and improvements to delirium and cognitive deficit saving hospitals $3B annually in the USA. Patients are safely migrated from higher to lower cost centers and ultimately discharge.
The drug product is a 505(b)2 submission, thus significantly reducing the the time and cost as pre-clinical studies have been bridged to the previously approved drug.
Our regulatory and clinical investigational plan completes the products development with a single Phase III trial that is set to enroll the first patient Q2 2021. The Series A funds the Phase III and submission of the NDA.
All in, 505(b)2 at $23M to exit, achieves US FDA approval, and addresses a $2.2B Service Obtainable Market!
The drug product is a 505(b)2 submission, thus significantly reducing the the time and cost as pre-clinical studies have been bridged to the previously approved drug.
Our regulatory and clinical investigational plan completes the products development with a single Phase III trial that is set to enroll the first patient Q2 2021. The Series A funds the Phase III and submission of the NDA.
All in, 505(b)2 at $23M to exit, achieves US FDA approval, and addresses a $2.2B Service Obtainable Market!
![](/sites/default/files/hubb_images/2996/attachments/%2520-%2520f1_OYE_20Therapeutics_2C_20Inc_f5471cd1.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Indiana
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Other
Lead Product in Development:
OYE-0519
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
![photo](/sites/default/files/hubb_images/2996/photos/user1.Dines.5e18c5a6.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved